Talaris Therapeutics to Participate at Two Upcoming Virtual Investor Conferences
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-stage cell therapy company, announced its participation in upcoming investor conferences. The company will host a fireside chat at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 13, 2021, at 5:00 PM ET. Additionally, Talaris will participate in the SVB Leerink CybeRx Series on September 22-23, 2021. A live webcast of the Morgan Stanley event will be available on its website and archived for 90 days.
Talaris focuses on innovative cell therapies for organ transplantation and severe autoimmune diseases.
- None.
- None.
BOSTON and LOUISVILLE, Ky., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced that members of its senior management team will participate at the following investor conferences:
Morgan Stanley Virtual 19th Annual Global Healthcare Conference
Fireside Chat Date: Monday, September 13, 2021
Time: 5:00 PM ET
SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1x1 Event
Date: September 22-23, 2021
A live webcast of the fireside chat at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference will be available on the investors section of the Talaris website at www.talaristx.com. After the live webcast, the event will remain archived on the Talaris website for 90 days.
About Talaris Therapeutics
Talaris Therapeutics, Inc. is a late-clinical stage biopharmaceutical company developing investigational, one-time, allogeneic cell therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders. Talaris maintains corporate offices in Boston, MA, and its cell processing facility in Louisville, KY. For additional information, visit talaristx.com, and follow us on Twitter, LinkedIn and Facebook.
Media Contact
Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
(617) 903-8783
Investor Contact
Chris Brinzey
Westwicke, an ICR Company
chris.brinzey@westwicke.com
(339) 970-2843
FAQ
When is Talaris Therapeutics participating in the Morgan Stanley Virtual Conference?
What is the focus of Talaris Therapeutics?
Where can I watch the Talaris Therapeutics fireside chat?
What are the dates for the SVB Leerink CybeRx Series event?
